View as cardsView as table

Novel biologics for cancer therapy

Fiscal Year Awarded:

2022

Principal Investigator:

George Church

Small molecule drugs for advanced cancer with ecDNA amplicons

Fiscal Year Awarded:

2022

Principal Investigator:

Timothy Mitchison

Small molecule modulators of bile acid metabolism to treat NAFLD/NASH

Fiscal Year Awarded:

2022

Principal Investigator:

Sloan Devlin

Studies on immunogenic lipids from the gut microbiome

Fiscal Year Awarded:

2022

Principal Investigator:

Jon Clardy

A novel biologic and therapeutic target for the treatment of diabetes

Fiscal Year Awarded:

2021

Principal Investigator:

Douglas Melton

Application of the SPLANDID antigen presentation technology to HIV-1 vaccine development

Fiscal Year Awarded:

2021

Principal Investigator:

James Chou

Development of an inexpensive at-home influenza kit and detection technology

Fiscal Year Awarded:

2021

Principal Investigator:

Michael Springer

Evaluating splicing modulators for therapeutic impact in cohesin-mutant AML and MDS cells

Fiscal Year Awarded:

2021

Principal Investigator:

Karen Adelman

Identifying novel therapeutic targets for treating pain and chronic itch

Fiscal Year Awarded:

2021

Principal Investigator:

David Ginty

Protein therapeutics for treatment of chronic and inflammatory pain

Fiscal Year Awarded:

2021

Principal Investigator:

Pamela Silver